胰高血糖素通过调节其结合蛋白降低人胰岛素样生长因子-1生物活性,且不依赖胰岛素
该双盲安慰剂对照研究在13例瘦对照、11例肥胖参与者和13例1型糖尿病患者中肌内注射胰高血糖素,观察到总胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3不变,但胰岛素样生长因子结合蛋白-1和结合蛋白-2升高,导致胰岛素样生长因子-1生物活性降低,且该降低先于生长激素升高;体外实验中胰高血糖素剂量依赖性诱导FOXO1核转位,并倾向增加小鼠原代肝细胞胰岛素样生长因子结合蛋白-1和结合蛋白-2基因表达,尽管Akt磷酸化缺失。
要点
- 胰高血糖素降低所有研究组的胰岛素样生长因子-1生物活性,与胰岛素水平变化无关。
- 胰高血糖素升高胰岛素样生长因子结合蛋白-1和结合蛋白-2,总胰岛素样生长因子-1和结合蛋白-3不变。
- 体外实验中胰高血糖素剂量依赖性诱导FOXO1核转位,可能通过FOXO/mTOR通路介导。
核心结论
- 数据提示胰高血糖素诱导的生物活性胰岛素样生长因子-1降低是胰高血糖素诱导生长激素分泌的机制。
- 这种不依赖胰岛素的降低与胰岛素样生长因子结合蛋白-1和结合蛋白-2水平升高有关,最可能通过FOXO/mTOR通路激活介导。
研究设计与样本
- 双盲、安慰剂对照研究,纳入13例瘦对照、11例肥胖参与者和13例1型糖尿病患者,肌内注射胰高血糖素。
- 体外实验研究胰高血糖素对人骨肉瘤细胞FOXO1转位、生长激素/胰岛素样生长因子-1系统成员转录及Akt磷酸化的影响。
主要发现
- 尽管总胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3水平不变,胰高血糖素通过增加胰岛素样生长因子结合蛋白-1和结合蛋白-2降低所有研究组的胰岛素样生长因子-1生物活性。
- 胰岛素样生长因子-1生物活性的降低发生在胰高血糖素诱导的生长激素升高之前。
- 与肥胖和瘦参与者循环胰岛素短暂增加相反,1型糖尿病患者中未观察到胰岛素变化。
- 体外实验中,胰高血糖素剂量依赖性诱导人骨肉瘤细胞FOXO1显著核转位,并倾向增加小鼠原代肝细胞胰岛素样生长因子结合蛋白-1和结合蛋白-2基因表达,尽管Akt磷酸化缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Depending on its lipolytic activity, glucagon plays a promising role in obesity treatment. Glucagon-induced growth hormone (GH) release can promote its effect on lipid metabolism, although the underlying mechanisms have not been well-defined. OBJECTIVE: The present study highlights the glucagon effect on the GH/insulinlike growth factor 1 (IGF-1)/IGF-binding protein (IGFBP) axis in vivo and in vitro, taking into consideration insulin as a confounding factor. MATERIALS AND METHODS: In a double-blind, placebo-controlled study, we investigated changes in GH, IGFBP, and IGF-1 bioactivity after intramuscular glucagon administration in 13 lean controls, 11 obese participants, and 13 patients with type 1 diabetes mellitus (T1DM). The effect of glucagon on the transcription factor forkhead box protein O1 (FOXO1) translocation, the transcription of GH/IGF-1 system members, and phosphorylation of protein kinase B (Akt) was further investigated in vitro. RESULTS: Despite unchanged total IGF-1 and IGFBP-3 levels, glucagon decreased IGF-1 bioactivity in all study groups by increasing IGFBP-1 and IGFBP-2. The reduction in IGF-1 bioactivity occurred before the glucagon-induced surge in GH. In contrast to the transient increase in circulating insulin in obese and lean participants, no change was observed in those with T1DM. In vitro, glucagon dose dependently induced a substantial nuclear translocation of FOXO1 in human osteosarcoma cells and tended to increase IGFBP-1 and IGFBP-2 gene expression in mouse primary hepatocytes, despite absent Akt phosphorylation. CONCLUSIONS: Our data point to the glucagon-induced decrease in bioactive IGF-1 levels as a mechanism through which glucagon induces GH secretion. This insulin-independent reduction is related to increased IGFBP-1 and IGFBP-2 levels, which are most likely mediated via activation of the FOXO/mTOR (mechanistic target of rapamycin) pathway.
引用
- Sarem Z, Bumke-Vogt C, Mahmoud AM, et al. Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins. J Clin Endocrinol Metab. 2017. PMID: 28911141. doi:10.1210/jc.2017-00558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。